

NC State Nephrology-Urology is enrolling patients with chronic kidney disease (CKD) to explore a new novel biomarker to aid in earlier detection of a common complication (acidosis) associated with kidney disease which will hopefully allow us to predict disease outcomes and therapeutic responses.

PARTICIPATION:

- Each dog will be seen for 4 study visits after enrollment into the study. These visits will occur every 3 months for one year
- At study enrollment each dog will have the following testing performed: a renal biochemistry panel, PCV/TP, urinalysis, urine protein-to-creatinine ratio, and blood pressure measurement
- At each study visit after enrollment each dog will have a renal biochemistry panel performed.

ELIGIBILITY:

- Dogs diagnosed with stable IRIS stage II -IV CKD (serum creatinine > 1.4 mg/dL or SDMA > 18 and lack of appropriate urine concentration, USG < 1.045)
- Dogs must be willing to eat a commercial renal diet (Purina NF, Royal Canin Renal Support, Hill's K/D)
- Criteria that exclude participation:
 - Evidence of lower urinary tract infection based on urinalysis or urine culture
 - Dogs receiving alkaline therapy (sodium bicarbonate or potassium citrate), diuretics or steroids.
 - Dogs diagnosed with Cushing's disease

For additional information contact the Harris Lab:



harrislab-clinicaltrials@ncsu.edu



